$-0.10 EPS Expected for BioScrip, Inc. (BIOS)

July 14, 2018 - By Paula Hilliard

BioScrip, Inc. (NASDAQ:BIOS) LogoInvestors sentiment increased to 1.39 in 2018 Q1. Its up 0.21, from 1.18 in 2017Q4. It increased, as 10 investors sold BioScrip, Inc. shares while 26 reduced holdings. 16 funds opened positions while 34 raised stakes. 106.54 million shares or 2.37% more from 104.07 million shares in 2017Q4 were reported.
Ares Mngmt Lc has 7.19 million shares. Barclays Public Ltd Liability Corp holds 0% or 24,232 shares. Gru owns 74,254 shares. Citigroup Inc stated it has 600 shares. Wells Fargo Mn holds 0% or 185,859 shares in its portfolio. Coliseum Management Ltd Liability has invested 1.87% in BioScrip, Inc. (NASDAQ:BIOS). State Street, a Massachusetts-based fund reported 2.13M shares. Texas-based United Services Automobile Association has invested 0% in BioScrip, Inc. (NASDAQ:BIOS). Jpmorgan Chase & accumulated 24,457 shares. 144,800 are owned by Raymond James Assoc. California State Teachers Retirement Sys stated it has 0% in BioScrip, Inc. (NASDAQ:BIOS). Deutsche National Bank Ag holds 3.16 million shares or 0.01% of its portfolio. Janney Montgomery Scott stated it has 0% in BioScrip, Inc. (NASDAQ:BIOS). Gamco Invsts Inc Et Al has invested 0.01% in BioScrip, Inc. (NASDAQ:BIOS). Diamond Hill Cap Mngmt holds 0.05% of its portfolio in BioScrip, Inc. (NASDAQ:BIOS) for 4.03M shares.

Analysts expect BioScrip, Inc. (NASDAQ:BIOS) to report $-0.10 EPS on August, 14.They anticipate $0.01 EPS change or 9.09 % from last quarter’s $-0.11 EPS. After having $-0.12 EPS previously, BioScrip, Inc.’s analysts see -16.67 % EPS growth. The stock decreased 4.76% or $0.15 during the last trading session, reaching $3. About 679,758 shares traded or 13.18% up from the average. BioScrip, Inc. (NASDAQ:BIOS) has risen 39.44% since July 14, 2017 and is uptrending. It has outperformed by 26.87% the S&P500.

BioScrip, Inc. (NASDAQ:BIOS) Ratings Coverage

Among 2 analysts covering BioScrip Inc (NASDAQ:BIOS), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. BioScrip Inc has $3.5000 highest and $3.25 lowest target. $3.38’s average target is 12.67% above currents $3 stock price. BioScrip Inc had 2 analyst reports since March 8, 2018 according to SRatingsIntel. On Thursday, March 8 the stock rating was maintained by SunTrust with “Buy”. Barrington maintained BioScrip, Inc. (NASDAQ:BIOS) rating on Wednesday, April 11. Barrington has “Buy” rating and $3.5000 target.

BioScrip, Inc. provides home infusion services in the United States. The company has market cap of $383.86 million. The firm engages in the preparation, delivery, administration, and clinical monitoring of pharmaceutical treatments that are administered to a patient through intravenous, subcutaneous, intramuscular, intra-spinal, and enteral methods. It currently has negative earnings. It is primarily involved in the intravenous administration of medications to treat a range of acute and chronic conditions, such as infections, nutritional deficiencies, immunologic and neurologic disorders, cancer, pain, and palliative care.

More news for BioScrip, Inc. (NASDAQ:BIOS) were recently published by: Profitconfidential.com, which released: “BIOS Stock Is All Set for an Explosive Move Toward Higher Prices” on July 09, 2018. Globenewswire.com‘s article titled: “BioScrip Appoints Richard Denness as Chief Commercial Officer” and published on July 10, 2018 is yet another important article.

BioScrip, Inc. (NASDAQ:BIOS) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.